



News

Merrill Lynch & Co., Inc.

Merrill Lynch Financial Centre
2 King Edward Street
London EC1A 1HQ

For information contact:

Merrill Lynch Media Relations:
Victoria Garrod +44 20 7995 4437
Victoria_garrod@ml.com

EUROMEDIC CONTINUES ITS GROWTH AND EXPANSION STRATEGY ACROSS EUROPE WITH THE BACKING OF A NEW SHAREHOLDER BASE

London, 13 June 2008 - Euromedic International Holdings B.V., a pan-European healthcare services provider headquartered in Budapest, secures Ares Life Sciences (ALS) and Merrill Lynch Global Private Equity (MLGPE) as new investors, who will acquire the company from its current shareholders led by Warburg Pincus. The new shareholders will continue to back the current management team, led by co-founders Joseph Priel (CEO) and Janos Mészáros (Chairman). Detailed terms of the transaction were not disclosed.

Euromedic is a fast-growing, pan-European medical services provider specializing in dialysis services and diagnostic imaging. The company recently entered the laboratory diagnostics and radiotherapy markets. Euromedic's services are provided across a network of 153 wholly-owned healthcare centres in 14 countries, in which the company contracts primarily with public insurance funds and hospitals. Euromedic benefits from increased levels of out-sourcing by governments, both as the result of the restructuring of existing healthcare service provision and the move to address unmet service requirements.

- END -

With the backing of its new shareholders, Euromedic will be able to further pursue its aggressive expansion strategy and strengthen its leading position in the growing and resilient dialysis and diagnostic imaging service markets across Eastern and Western Europe. The company is broadening its reach and extending its services into laboratory diagnostics and radiotherapy within existing geographies and selectively expanding its geographic footprint.

Commenting on the acquisition, Matthew Turner, European Head of MLGPE said: "We see in Euromedic a very high quality business with an excellent management team that has a strong service offering in high-growth markets. We are very excited to be supporting the company in pursuing its expansion strategy."

Jacques Theurillat, CEO of Ares Life Sciences added: "We very much look forward to supporting management in its plan and to provide them with our full backing in exploiting the company's potential."

Commenting on the investment, Nick Lowcock, a senior advisor of Warburg Pincus in Europe, said: "We have backed Euromedic during a period of significant growth and consolidated its position as leader in its markets, entering ten new geographies through both organic growth and acquisitions. We would like to thank Joseph Priel and Janos Mészáros, and their country management teams and staff for their hard work in making this a successful investment for us. We are confident of Euromedic's continued success."

Joseph Priel, CEO of Euromedic said: "In partnership with Warburg Pincus, we have been able to rapidly grow Euromedic, leading it from strength to strength, and we are extremely grateful for their support. We now see a significant opportunity to further expand our business, which will be facilitated by the full backing of MLGPE and Ares Life Sciences."

Merrill Lynch Investment Banking acted as advisor to MLGPE and Ares Life Sciences.

Financing for the transaction is being provided by ING, Unicredit and Bank of Ireland.

For further information please contact:

For Merrill Lynch Global Private Equity:

Victoria Garrod

Tel: +44 (0)20 7995 4437

For Warburg Pincus:

Citigate Dewe Rogerson

Angharad Couch / Nicola Smith

Tel: +44 (0)20 7638 9571

Notes to Editors:

About Euromedic:

Euromedic, headquartered in Budapest, Hungary, is a fast growing, pan-European provider of a broad range of healthcare services. The company employs 4,500 people and contracts primarily with public insurance funds and hospitals, and its current principal healthcare service lines are dialysis, diagnostic imaging, laboratory diagnostics and radiotherapy. Euromedic also provides diagnostic imaging equipment training services. The company's services are provided across a network of 153 wholly-owned healthcare centres in 14 countries. For more information please visit www.euromedic.com.

About Ares Life Sciences (ALS):

Ares Life Sciences (ALS) is an investment venture backed by former executives from Serono. ALS actively seeks and invests in EU based healthcare opportunities.

About Merrill Lynch Global Private Equity (MLPGE):

Merrill Lynch Global Private Equity (MLGPE) is the private equity arm of Merrill Lynch & Co, Inc. MLGPE's investment strategy is focused on companies with proven business models and exceptional management teams, across a variety of sectors. MLGPE has in excess of \$5.0 billion equity invested in portfolio companies, with over 70 professionals located in London, New York, São Paulo, Tokyo, Sydney, Hong Kong and Mumbai, leveraging its global footprint of offices and the Merrill Lynch network to the benefit of its portfolio companies, bringing contacts, relationships and expertise. For more information, please visit <http://gmi.ml.com/private/>

About Warburg Pincus:

Warburg Pincus has been a leading private equity investor since 1971. The firm currently has more than \$35 billion of assets under management. Warburg Pincus' investments are focused on a range of sectors in North America, Europe and Asia, including healthcare, financial services, industrial, technology, media and telecommunications, energy, consumer and retail, and real estate. Since inception, the firm has raised 13 private equity funds that have invested over \$31 billion in approximately 600 companies in more than 30 countries. Warburg Pincus currently has an active portfolio of more than 125 companies. The firm has 59 managing directors and more than 160 professionals in Beijing, Frankfurt, Hong Kong, London, Mumbai, New York, San Francisco, Shanghai and Tokyo. For more information please visit www.warburgpincus.com.

###

-END-